284 POSTER Lenalidomide and CC-4047 inhibit the proliferation of Namalwa cancer cells while expanding CD34+ progenitor cells. New insights on the combination therapy with HDAC inhibitors for hematological cancers
Dominique Verhelle(Pfizer (United States)), Kyle Chan, Gregory D. Ferguson(Ferring Pharmaceuticals (United Kingdom)), Laure Moutouh–de Parseval, Kristen Jensen-Pergakes, Emilia Glezer, Jessica H. Mueller, Katie Wong, Laura G. Corral, Helen Brady
Cited by 0
Related Papers
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
|Cancer Research|2007|232
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
|Journal of Clinical Investigation|2008|180
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
|Cancer Research|2009|170
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)
|Journal of Medicinal Chemistry|2017|129